Search research articles
Contact Us
Filters
Showing results (131-140 of 137) with videos related to
Page
of 14
Sort By:
You have reached the last page of results.
This site can display upto 137 results.
Breast Cancer Research and Treatment
|
December 28, 2014
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study
A R Tan, H Johannes, P Rastogi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 30, 2022
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
C E Geyer, W M Sikov, J Huober, et al.
The New England Journal of Medicine
|
July 2, 1981
Treatment of primary breast cancer with chemotherapy and tamoxifen
B Fisher, C Redmond, A Brown, et al.
Journal of the National Cancer Institute
|
November 6, 1996
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
B Fisher, J Dignam, J Bryant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 5, 1999
Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25
B Fisher, S Anderson, A DeCillis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 2021
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE
E P Mamounas, M Untch, M S Mano, et al.
Breast Cancer Research : BCR
|
January 24, 2025
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
A DeMichele, A C Dueck, D Hlauschek, et al.
Page
of 14
Search research articles
Search
Showing results (131-140 of 137) with videos related to
Sort By:
Page
of 14
You have reached the last page of results.
This site can display upto 137 results.
Breast Cancer Research and Treatment
|
December 28, 2014
Weekly paclitaxel and concurrent pazopanib following doxorubicin and cyclophosphamide as neoadjuvant therapy for HER-negative locally advanced breast cancer: NSABP Foundation FB-6, a phase II study
A R Tan, H Johannes, P Rastogi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 30, 2022
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
C E Geyer, W M Sikov, J Huober, et al.
The New England Journal of Medicine
|
July 2, 1981
Treatment of primary breast cancer with chemotherapy and tamoxifen
B Fisher, C Redmond, A Brown, et al.
Journal of the National Cancer Institute
|
November 6, 1996
Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors
B Fisher, J Dignam, J Bryant, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 5, 1999
Further evaluation of intensified and increased total dose of cyclophosphamide for the treatment of primary breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-25
B Fisher, S Anderson, A DeCillis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 1, 2021
Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE
E P Mamounas, M Untch, M S Mano, et al.
Breast Cancer Research : BCR
|
January 24, 2025
Outcomes in stage IIA versus stage IIB/III in the PALLAS trial [ABCSG-42/AFT-05/PrE0109/BIG-14-13])
A DeMichele, A C Dueck, D Hlauschek, et al.
Page
of 14